Avelox moxifloxacin: Phase II data

In a Phase II trial in 344 evaluable patients, moxifloxacin plus rifampin, pyrazinamide and ethambutol missed the primary endpoint of improved 2-month culture conversion vs. isoniazid plus rifampin, p...